Larimar's Q2 Update: Cash $156M, Nomlabofusp BLA on Track, Strong Open-Label Data
LRMR sits 40% above its 52-week low of $2.715 on light trading volume (0.4× avg).
Summary
Larimar reported Q2 2026 financials with $156.3M in cash, down from $200.4M at Q1, but still funding operations into Q2 2027. The update includes robust open-label data for nomlabofusp in Friedreich's ataxia: 43 participants dosed, sustained frataxin increases, and a 2.6-point mFARS benefit at one year. FDA alignment on the rolling BLA submission was confirmed, with completion expected in H2 2026. The company also plans to start dosing in a global confirmatory study this quarter. This follows the June BLA module submission and May shareholder approval for increased authorized shares. The clinical data strengthens the case for accelerated approval, and the cash runway provides a buffer through key regulatory milestones.
At the time of this announcement, LRMR was trading at $3.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $413.5M. The 52-week trading range was $2.72 to $6.42. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.